Accurate diagnosis plays a crucial role in ensuring effective treatment.. This belief is at the heart of our work with melanoid melanoma and next-generation sequencing (NGS). Diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are complex and aggressive. They often arise from genetic changes that can be difficult to detect using traditional methods. This is the place where our Myeloid Profiler DNA Panel arrives – a reliable and sensitive myeloid NGS panel created for today’s clinical and research requirements.

What Are Myeloid Malignancies?

Myeloid malignancies are a group of cancers that originate in the bone marrow the soft, spongy tissue where blood cells are produced. These cancers affect myeloid cells, which typically develop into red blood cells, white blood cells, or platelets.

Common types of myeloid malignancies include:

• Acute Myeloid Leukemia (AML)

• Myelodysplastic Syndromes (MDS)

• Chronic Myelomonocytic Leukemia (CMML)

• Juvenile Myelomonocytic Leukemia (JMML)

These conditions tend to grow quickly, involve complex genetic changes, and can be challenging to treat.Early and accurate diagnosis especially with genetic testing—is crucial for effective disease management.

Each type is marked by specific gene mutations, fusions, or rearrangements. Understanding these genetic changes is essential to making accurate diagnoses and choosing the right treatment.

Why Is Early and Accurate Diagnosis Important?

In fast-moving cancers like AML, time is everything. The sooner you are diagnosed, the sooner you can act. But more than speed, accuracy is critical. Treatment based on an incomplete or incorrect diagnosis can cause more harm than well.

An accurate diagnosis helps with:

• Choosing targeted  therapies
• Predicting the progression of the disease
• Decide on cell transplantation
• Avoiding ineffective or harmful treatments

This is why having a comprehensive myeloid malignancies mutation panel like the one offered at Uncoded, is a game-changer.

How Does NGS Work in Simple Terms?

Next-generation sequencing (NGS) is a powerful laboratory technology that reads genetic material at a rapid speed. Instead of testing one mutation at a time, NGS checks thousands of genes at once.

Here’s how it works:

• DNA is extracted from a patient sample (such as bone marrow)
• It is converted into a format that NGS machines can read
• Data are processed to identify gene fusions, mutations and rearrangements

The result? A complete image of what is going wrong at the molecular level.

Why Choose NGS Over Traditional Methods?

Traditional tests like PCR are good but limited. They often look for only a few mutations at a time. That means you might miss something important.

NGS is broader, deeper, and faster.

• Detects known and novel gene fusions
• Works on smaller sample sizes
• Picks up even low-frequency variants

When you’re working with complex diseases like myeloid cancers, you need all the information you can get. That’s why our myeloid NGS solution is built to dig deeper.

Which Myeloid Mutations Can NGS Detect?

With our Myeloid Profiler DNA Panel, you can detect:

• Over 75 known gene fusions linked to myeloid malignancies
• 41 genes with full CDS (coding DNA sequence) for in-depth variant analysis

This also includes 41 genes with full CDS, for in-depth variant analysis.

Some key targets include:

• RUNX1-RUNX1T1
• CBFB-MYH11
• PML-RARA
• BCR-ABL1 (common in CML but occasionally seen in AML)

These mutations directly impact treatment options and prognosis. The better we detect, the better we treat.

How Is NGS Used in Clinical Practice?

Doctors and researchers use myeloid NGS panels in several ways:

• Initial diagnosis: To confirm the type of myeloid cancer
• Therapy planning: To match patients with targeted drugs
• Monitoring: To track treatment response or relapse
• Clinical trials: To qualify patients based on specific mutations

Our Myeloid Profiler DNA Panel is built with this clinical flexibility in mind.

What Are the Benefits of NGS for Doctors and Patients?

Let’s look at how our NGS-based myeloid panel test helps both doctors and patients:

For Clinicians:

• Quick, reliable test results
• Comprehensive data in one go
• Helps build precise treatment plans

For Patients:

• Less invasive testing
• Faster answers during a stressful time
• Personalized treatment options

Are There Any Limitations or Challenges of NGS?

As promising as NGS is, it isn’t without challenges:

• Data interpretation: Requires skilled analysis
• Sample quality: Low-quality DNA can affect results
• Cost: May be higher than traditional tests

That’s why we’ve made our panel robust and efficient. Even with genomic DNA (gDNA) extracted from blood and bone marrow, our panel delivers high-quality results even from minimal samples.

How Do NGS Panels Differ? (Comprehensive vs Targeted)

Not all NGS tests are the same. Some are broad panels that scan the whole genome. Others, like ours, are focused but deep.

Our Myeloid Profiler DNA Panel is:

• Targeted: Built specifically for myeloid malignancies
• Comprehensive: Covers known and novel fusion variants
• Efficient: Optimized for lab workflows

This balance makes it ideal for real-world clinical use.

What Should You Ask Your Doctor Before an NGS Test?

If you’re a patient or caregiver, consider asking:

• Is an NGS test recommended for my condition?
• What kind of results will it provide?
• How will it impact my treatment?
• Is it covered by insurance?

These questions can help you make informed decisions.

What Are the Costs and Accessibility of NGS in India?

In India, access to NGS testing is improving. While it can still be expensive, companies like ours are working to make it more accessible.

We focus on affordability and quick turnaround times without compromising quality. Our streamlined workflow helps hospitals and labs deliver results faster, making the technology more practical and scalable.

Can NGS Predict Treatment Response or Prognosis?

Yes, in many cases, the type of mutation or fusion can indicate how well a patient might respond to treatment.

For example:

• FLT3 mutations may respond to FLT3 inhibitors
• IDH1/2 mutations open doors to targeted therapies

Knowing these details early gives oncologists an edge in building the right plan.

Is NGS Covered by Insurance or Government Health Schemes?

The coverage depends on the provider and the region. Some private insurance companies and government health initiatives have begun to recognize the importance of myeloid NGS panels.

As technology becomes more common, we expect broader acceptance and better refund options. At Uncoded, we support institutions that want to integrate these tests into broader service programs.

What’s the Future of NGS in Myeloid Cancer Care?

The future is brilliant. As more therapies become specific to mutation, the need for precise tests will only grow.

We are already seeing:

• NGS is being used for tracking minimum residual diseases
• Real-time monitoring through liquid biopsies
• NGS data interpretation assisted by AI 

Our goal at Uncoded is to remain at the forefront of this evolution. With tools such as the Myeloid Profiler DNA Panel, we are not just diagnosing; We are enabling doctors and patients to make the best possible decisions.

Conclusion

The diagnosis of myeloid cancers is no longer about divination. With next-generation sequencing in myeloid malignancies, we can discover the complex genetic scenario that drives each patient’s disease. Our Myeloid Profiler DNA Panel facilitates the detection of rare fusion genes with high sensitivity and specificity.

At Uncoded, we are proud to create tools that do not follow the diagnosis of cancer but help to redefine it. If you are looking for an efficient and reliable myeloid NGS panel, we are here to support your work.

Because behind each test result is a patient waiting for answers. And we are here to deliver them.